文献速递浆细胞疾病

RNA聚合酶I抑制剂CX-5461作为靶向多发性骨髓瘤MYC的新型治疗策略

RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
PubMed 文献 · Br J Haematol · 2017-01-01

本研究探讨小分子RNA聚合酶I抑制剂CX-5461在多发性骨髓瘤中靶向核糖体生物合成的效果。CX-5461在野生型和突变型TP53骨髓瘤细胞系及原代样本中诱导显著生长抑制,并增加凋亡下游标志物,同时克服黏附介导的耐药及对传统和新型药物的耐药。机制上CX-5461快速抑制MYC蛋白和mRNA水平,后者与RISC亚基TARBP2、AGO2、核糖体蛋白RPL5及MYC mRNA结合增加导致MYC转录降解有关,为CX-5461靶向骨髓瘤MYC的临床转化提供依据。

要点

  • CX-5461在野生型和突变型TP53骨髓瘤细胞系及原代样本中诱导显著生长抑制。
  • CX-5461克服黏附介导的耐药及对传统和新型药物的耐药。
  • CX-5461快速抑制MYC蛋白和mRNA水平,通过RISC亚基及RPL5增加MYC转录降解。

核心结论

  • 这些研究为CX-5461作为靶向骨髓瘤MYC的新型治疗方法的临床转化提供了依据。

研究设计与样本

  • 研究使用野生型和突变型TP53骨髓瘤细胞系及原代样本,并进行同基因TP53野生型和敲除细胞系的基因表达谱分析。

主要发现

  • CX-5461在野生型和突变型TP53骨髓瘤细胞系及原代样本中诱导显著生长抑制,并增加凋亡下游标志物。
  • CX-5461克服黏附介导的耐药及对传统和新型药物的耐药。
  • 同基因TP53野生型和敲除细胞系的基因表达谱显示MYC下游靶点减少。
  • CX-5461快速抑制MYC蛋白和MYC mRNA水平,后者与RISC亚基TARBP2、AGO2、核糖体蛋白RPL5及MYC mRNA结合增加相关,导致MYC转录降解增加。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dysregulation of MYC is frequently implicated in both early and late myeloma progression events, yet its therapeutic targeting has remained a challenge. Among key MYC downstream targets is ribosomal biogenesis, enabling increases in protein translational capacity necessary to support the growth and self-renewal programmes of malignant cells. We therefore explored the selective targeting of ribosomal biogenesis with the small molecule RNA polymerase (pol) I inhibitor CX-5461 in myeloma. CX-5461 induced significant growth inhibition in wild-type (WT) and mutant TP53 myeloma cell lines and primary samples, in association with increases in downstream markers of apoptosis. Moreover, Pol I inhibition overcame adhesion-mediated drug resistance and resistance to conventional and novel agents. To probe the TP53-independent mechanisms of CX-5461, gene expression profiling was performed on isogenic TP53 WT and knockout cell lines and revealed reduction of MYC downstream targets. Mechanistic studies confirmed that CX-5461 rapidly suppressed both MYC protein and MYC mRNA levels. The latter was associated with an increased binding of the RNA-induced silencing complex (RISC) subunits TARBP2 and AGO2, the ribosomal protein RPL5, and MYC mRNA, resulting in increased MYC transcript degradation. Collectively, these studies provide a rationale for the clinical translation of CX-5461 as a novel therapeutic approach to target MYC in myeloma.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Lee HC, Wang H, Baladandayuthapani V, et al. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma. Br J Haematol. 2017. PMID: 28369725. doi:10.1111/bjh.14525

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。